Labcorp Holdings LH Biopharma Laboratory Services — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Labcorp Holdings in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Labcorp Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Labcorp Holdings's biopharma laboratory services — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Labcorp Holdings's biopharma laboratory services — operating income?
- Labcorp Holdings (LH) reported biopharma laboratory services — operating income of $120.7M in Q1 2026.
- How has Labcorp Holdings's biopharma laboratory services — operating income changed year-over-year?
- Labcorp Holdings's biopharma laboratory services — operating income increased by 12.9% year-over-year, from $106.9M to $120.7M.
- What is the long-term trend for Labcorp Holdings's biopharma laboratory services — operating income?
- Over 3 years (2022 to 2025), Labcorp Holdings's biopharma laboratory services — operating income has grown at a 8.6% compound annual growth rate (CAGR), from $389.1M to $498.5M.
- What does biopharma laboratory services — operating income mean?
- This metric measures the profitability of the Biopharma Laboratory Services segment by subtracting all direct and indirect operating expenses from the segment's total revenue. It reflects the core operational performance and margin generation capability of the business unit before interest and taxes. It is a primary indicator of the segment's ability to convert laboratory service volume into sustainable earnings.